Rilzabrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria unresponsive to antihistamines, in a phase 2 study.
Rilzabrutinib, an oral inhibitor of Bruton tyrosine kinase , demonstrated a rapid and substantial alleviation of symptoms in patients with chronic spontaneous urticaria unresponsive to antihistamines at a dosage of 1200 mg/d compared with placebo.
Researchers conducted a 52-week phase 2 trial comprising a 12-week double-blind, placebo-controlled period followed by a 40-week open-label extension across 51 centers in 12 countries in Asia, Europe, North America, and South America. A total of 160 participants with moderate to severe CSU who were not adequately controlled with H1 antihistamine treatment were randomly assigned to receive rilzabrutinib at doses of 400 mg daily, 800 mg daily, 1200 mg daily, or placebo for 12 weeks. For the United States and US reference countries, the primary and secondary endpoints were the change from baseline at week 12 in ISS7 and UAS7, respectively. For non–US reference countries, the change from baseline in UAS7 was the primary outcome, while ISS7 served as the secondary endpoint.Improvements in symptoms were observed as early as week 1, with an LS mean difference for ISS7 of −4.21 and UAS7 of −7.89 .=.03). A higher proportion of patients treated with rilzabrutinib, 1200 mg/d, achieved well-controlled disease than those receiving placebo . Rilzabrutinib demonstrated a favorable risk-benefit profile, with no new safety concerns. Diarrhea and nausea were the most common adverse events.“The results of this randomized clinical trial demonstrated that rilzabrutinib may be an effective BTKI with a favorable risk-benefit profile for the treatment of H1 antihistamine-refractory patients with CSU,” authors of the study wrote. More research is needed to “determine long-term efficacy and potential harms,” they added.The study was led by Ana Giménez-Arnau, MD, PhD, Hospital del Mar Medical Research Institute, Universitat Pompeu Fabra, Barcelona, Spain, and wasThe study had a small sample size, limited racial diversity, a low number of omalizumab-incomplete responders, and a short duration of follow-up.This work was supported by Sanofi. Giménez-Arnau reported receiving grants and personal fees from various companies, including Novartis, and serving as principal investigator for clinical trials sponsored by AstraZeneca, Celldex Therapeutics, Escient Pharmaceuticals, and LEO Pharma. Other authors reported holding stocks in Sanofi and having a pending patent for a method of CSU treatment. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
Urticaria And Angio-Oedema Urticaria Hives Antihistamine Healthcare And Medical Technology Health And Medical Tech Health And Med Tech Health And Medical Technology Healthcare Technology Medical Technology Pruritus Pruritis Itch Clinical Research Clinical Trials Clinical Studies Pre-Clinical Trial Double-Blind Study Double-Blind Studies Single-Blind Study
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
A unique sound alleviates motion sicknessA research group has discovered that using a device that stimulates the inner ear with a specific wavelength of sound reduces motion sickness. Even a single minute of stimulation with a unique sound, called 'sound spice ,' reduced the staggering and discomfort felt by people that were asked to read a document in a moving vehicle.
Read more »
Effective strategies for overcoming chronic worry can hel you reclaim your life.Why we worry, what we worry about, and 5 steps we can take to break free of unhealthy cycles of negative forecasting.
Read more »
Chronic Stress Is Harmful To Our Health — But Is It Reversible?They're simple, but that doesn't mean they're easy.
Read more »
What I Wish I Knew About Treating Chronic Pain in People With Psoriatic ArthritisA rheumatologist discusses how her understanding of chronic pain in PsA has evolved—and how it affects her approach to treatment and patient communication.
Read more »
Dupilumab Approved for Chronic Spontaneous UrticariaResubmission of the supplemental biologics license application provided more data on improvement in hives and itching in patients ages 12 and older with CSU.
Read more »
All chronic complainers should establish this ratioAre you finding yourself complaining about something that you believe you can't change, again and again? Do you see others doing so? Here's a way to get past all that.
Read more »